<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02630836</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-MT-10-03</org_study_id>
    <secondary_id>2010-024041-78</secondary_id>
    <nct_id>NCT02630836</nct_id>
  </id_info>
  <brief_title>Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture</brief_title>
  <official_title>A Pilot Clinical Trial of ex Vivo Expanded Allogenic Adult Stem Cells Combined With Allogenic Human Bone Tissue (XCEL-MT-OSTEO-BETA) in Proximal Femur Fractures in Elderly Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, unicenter, randomized, open-label, single-dose, two-arms blinded assessor pilot
      study. Thirty-two (32) elderly patients with hip fracture will be randomized to one of the
      two treatment-arms (Xcel-MT-osteo-beta or Standard treatment) and be followed for 12 month
      with the primary objective of safety. Secondary objectives are efficacy through axial
      tomography and xRay, clinical efficacy and quality of life questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, unicenter, randomized, open-label, single-dose, two-arms blinded assessor phase
      I-II pilot study.

      Thirty-two (32) elderly patients (70-85 years of age) with type 31A2 y 31A3 fracture of the
      femur (AO/ASIF (Association for the Study of Internal Fixation) classification) admitted at
      the emergency room of the Hospital Clinic of Barcelona will be randomized 1:1 to one of the
      two treatment-arms (endomedullary nailing + XCEL-MT-OSTEO-BETA or isolated endomedullary
      nailing as the standard treatment). Once surgically treated, patients will be followed for 12
      month with the primary objective of safety. Secondary objectives are efficacy through axial
      tomography and xRay, clinical efficacy and quality of life questionnaire (EUROQOL-5D).
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of XCEL-MT-OSTEO-BETA in proximal femur fractures by Adverse events, physical exam, laboratory tests.</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events, physical exam, laboratory tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy through CT scan</measure>
    <time_frame>3 months</time_frame>
    <description>assessment of consolidation by determination of Hounsfield units in CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy through xRay</measure>
    <time_frame>1, 3 and 6 months</time_frame>
    <description>assessment of bone callus characteristics by standard radiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy by clinical assessment</measure>
    <time_frame>1, 3 and 6 month</time_frame>
    <description>Clinical assessment by visual analogue scale for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy by quality of life questionnaire</measure>
    <time_frame>3, 6 and 12 month</time_frame>
    <description>EUROQoL-5D quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Femoral Neck Fracture</condition>
  <arm_group>
    <arm_group_label>XCEL-MT-OSTEO-BETA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard surgical treatment with isolated endomedullary nailing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XCEL-MT-OSTEO-BETA</intervention_name>
    <description>XCEL-MT-OSTEO-BETA followed by endomedullary nailing</description>
    <arm_group_label>XCEL-MT-OSTEO-BETA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical treatment</intervention_name>
    <description>Isolated endomedullary nailing</description>
    <arm_group_label>XCEL-MT-OSTEO-BETA</arm_group_label>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient between70 and 85 years old

          2. Proximal femur fracture type 31A3 31a2 classification AO/ASIF.

          3. Deambulation prior to fracture.

          4. Written informed consent of the patient or family members.

        Exclusion Criteria:

          1. Presence of implants at proximal femur level.

          2. Presence of local or systemic septic process.

          3. Septic arthritis.

          4. Dementia of any type.

          5. Hematological and biochemical analysis with significant alterations that
             contraindicate surgery.

          6. Patients with positive serology for HIV 1 and 2, Hepatitis B, Hepatitis C and
             syphilis.

          7. Neoplastic disease detected in the last five years or without complete remission.

          8. Immunosuppressive status.

          9. Patients who received corticosteroids in the 3 months prior to study initiation.

         10. Simultaneous participation in another clinical trial or treatment with another
             investigational product within 3 months prior to inclusion in the study.

         11. Other conditions or circumstances that may compromise the patient's participation in
             the study according to medical criteria.

         12. Patient refusal to be followed by a period that may exceed the clinical trial itself.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Maria Segur, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic de Barcelona</affiliation>
  </overall_official>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://bancsang.net</url>
    <description>Blood and Tissue Banc of Catalonia</description>
  </link>
  <link>
    <url>http://hospitalclinic.org</url>
    <description>Hospital Clínic de Barcelona</description>
  </link>
  <link>
    <url>http://fundacioclinic.org</url>
    <description>Hospital Clinic Foundation</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stromal cells</keyword>
  <keyword>stem cells</keyword>
  <keyword>elderly</keyword>
  <keyword>allogeneic</keyword>
  <keyword>bone marrow</keyword>
  <keyword>bone regeneration</keyword>
  <keyword>fracture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Neck Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

